Skip to main content

Search Videos

Showing 85 - 95 of 95 results

Previous| 1... 6 | 7 | 8 |Next

Can you give us a roadmap and detailed rationale for how and when to deploy NGS in the setting of prostate cancer? How do improve the content yields of prostate biopsies? How do we ferret out tumor heterogeneity issues?

Can you give us a roadmap and detailed rationale for how and when to deploy NGS in the setting of prostate cancer? How do improve the content yields of prostate biopsies? How do we ferret out tumor heterogeneity issues?

Using FoundationOne NGS-based whole exome profiling, what foundational and clinically actionable information is provided, and how should clinicians apply findings to the front lines of practice?

Using FoundationOne NGS-based whole exome profiling, what foundational and clinically actionable information is provided, and how should clinicians apply findings to the front lines of practice?

Why is whole genome sequencing with NGS uniquely applicable to patients with NSCLC?

Why is whole genome sequencing with NGS uniquely applicable to patients with NSCLC?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

What specific and actionable molecular derangements are identified by NGS to guide targeted therapy?

What specific and actionable molecular derangements are identified by NGS to guide targeted therapy?

What are the validations that larger molecular profiling panels -- using NGS to interrogate several hundred genes and provide comprehensive genomic profiles -- are superior to targeted or hot spot panels?

What are the validations that larger molecular profiling panels -- using NGS to interrogate several hundred genes and provide comprehensive genomic profiles -- are superior to targeted or hot spot panels?

Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling?

Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling?

Can you provide a specific patient example -- in a patient with EGFR-positive NSCLC -- where ctDNA may redirect treatment?

Can you provide a specific patient example -- in a patient with EGFR-positive NSCLC -- where ctDNA may redirect treatment?

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean)

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean)

When evaluating receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability as important as expression of the IC receptor?

When evaluating receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability as important as expression of the IC receptor?

What is the importance of ALK fusion mutations? What are the therapeutic implications of detection? How effective are second-generation ALK inhibitors? What does the data show as far as PFS?

What is the importance of ALK fusion mutations? What are the therapeutic implications of detection? How effective are second-generation ALK inhibitors? What does the data show as far as PFS?

Showing 85 - 95 of 95 results

Previous| 1... 6 | 7 | 8 |Next